Novavax, Inc. $NVAX Shares Sold by Eversept Partners LP

Eversept Partners LP reduced its position in Novavax, Inc. (NASDAQ:NVAX) by 25.5% in the 4th quarter, Holdings Channel reports. The firm owned 181,220 shares of the biopharmaceutical company’s stock after selling 61,964 shares during the period. Eversept Partners LP’s holdings in Novavax were worth $1,218,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in NVAX. AQR Capital Management LLC lifted its stake in Novavax by 95.2% in the first quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 21,663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Novavax by 2.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock valued at $678,000 after acquiring an additional 2,750 shares during the period. Caxton Associates LLP purchased a new stake in Novavax in the 1st quarter valued at $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Novavax by 16.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company’s stock worth $2,005,000 after purchasing an additional 44,105 shares during the period. Finally, Strs Ohio purchased a new position in Novavax during the 1st quarter worth $167,000. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Price Performance

Shares of NVAX stock opened at $9.50 on Thursday. The business’s fifty day moving average price is $9.06 and its 200 day moving average price is $8.61. The firm has a market capitalization of $1.56 billion, a PE ratio of -16.38 and a beta of 2.45. Novavax, Inc. has a 1-year low of $6.13 and a 1-year high of $11.97.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. Novavax had a negative net margin of 14.73% and a negative return on equity of 14.82%. The business had revenue of $118.90 million during the quarter, compared to the consensus estimate of $79.81 million. During the same quarter last year, the firm posted $2.93 EPS. The business’s revenue was down 79.0% compared to the same quarter last year. Equities research analysts expect that Novavax, Inc. will post -0.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research note on Sunday, May 31st. B. Riley Financial reiterated a “buy” rating on shares of Novavax in a research note on Thursday, April 9th. Weiss Ratings downgraded Novavax from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, May 7th. Jefferies Financial Group reissued a “buy” rating on shares of Novavax in a research note on Thursday, March 12th. Finally, HC Wainwright raised their target price on shares of Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $13.00.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.